Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the effectiveness of finasteride and microneedling for treating hair loss. The linked article is seen as an advertisement for these treatments.

The conversation discusses concerns about importing Koshine KX, a hair loss treatment. A user reassures that there is no risk of getting caught.

Finasteride and Dutasteride are under review in the EU due to concerns about side effects like depression, but they are unlikely to be banned. Access to these medications varies, with easier availability in the UK compared to some EU countries.

The conversation discusses the link between increased estrogen and autoimmune diseases, with a focus on avoiding soy and milk. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The conversation is about trying dutasteride mesotherapy for hair loss, with concerns about its effectiveness and potential side effects compared to finasteride. The user is considering this treatment available in California.

Pyrilutamide 0.9% (kx-826) is available for shipping to Europe from Amazon US and Koshinemall. Shipping costs and availability vary between the two shops.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

Best future hair loss treatment discussed: verteporfin, kx-826, and GT20029. Verteporfin could potentially end baldness with scarless procedures.

Finasteride may pose a risk during pregnancy, so using a condom is recommended if a partner is pregnant. It is advised to stop finasteride before trying to conceive due to potential effects on fetal development.

Minoxidil, finasteride, and RU58841 are discussed as hair loss treatments. User skepticism is expressed about the effectiveness of these treatments.

CRISPR Cas9 could potentially treat baldness by targeting specific genes in hair follicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

The user is experimenting with a zinc sulfate and B6 topical solution called "Zix" for hair loss, alongside using a zinc oxide scalp mask and low-level laser therapy (LLLT). They report minimal hair loss after three months of use and are seeking feedback from others who have tried similar treatments.

Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.

A user has been treating hair loss with finasteride for two years without success and is experiencing an itchy scalp with seborrhea. Despite low DHT levels, they are still losing hair, suggesting that DHT might not be the main cause of their hair loss, and they are considering other treatments or causes.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A user is seeking a 15% Minoxidil solution without finasteride or azelaic acid, as they can no longer find it. Another user is curious about the results of using the 15% Minoxidil.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

People are discussing the effectiveness of Breezula for hair loss maintenance. Some individuals are using Breezula alone, avoiding finasteride, and one plans to use Breezula after a hair transplant.

The user has been using finasteride, dutasteride, and RU58841 for hair loss without success and feels extremely uncomfortable with their appearance, including being bald and short. They express deep unhappiness and social isolation. Suggestions from others include adopting stoicism, focusing on personal development, considering a hair system, improving fashion, working out, and seeking therapy for mental health.

The conversation discusses skepticism about Breezula, a hair loss treatment, with the consensus that it's not a miracle cure but a maintenance drug that may work well with finasteride. Some users report side effects from finasteride, like sexual dysfunction, while hoping for better results from Breezula or RU58841 without such side effects.

A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

Hair transplants, oral finasteride, oral minoxidil, and dutasteride mesotherapy are highly effective for treating AGA hair loss. This combination can maintain and improve hair for most people, except those with very aggressive AGA.